MOTS-c vs PT-141 (Bremelanotide)

Mechanism

MOTS-c is a 16-amino acid mitochondrial-derived peptide encoded by the 12S rRNA gene of the mitochondrial genome. It primarily acts through the folate-AICAR-AMPK pathway: by regulating the folate cycle and de novo purine biosynthesis, it increases AICAR accumulation, which phosphorylates and activates AMPK. This enhances glucose uptake in skeletal muscle, improves insulin sensitivity, and mimics exercise-mediated physiological responses. Skeletal muscle MOTS-c levels increase 11.9-fold in response to acute exercise in young men.

Standard Dosing

Research indicates 5-10 mg administered 3-5 times per week via subcutaneous injection.

Timing

Morning administration preferred. Can be dosed pre-workout for enhanced exercise performance.

Cycle Duration

8-16 week cycles.

Side Effects

• Injection site reactions
• Mild fatigue post-injection
• Transient flushing
• Muscle soreness (exercise-mimetic effect)

Contraindications

• Pregnancy and breastfeeding
• Type 1 diabetes (insulin sensitivity changes require monitoring)
• Not FDA-approved
• Limited human safety data
• Active cancer (metabolic pathway activation)

Best Stacking Partners

Mechanism

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide melanocortin analog that acts as an agonist at MC3R and MC4R melanocortin receptors, with higher affinity for MC4R. It enhances sexual desire by activating presynaptic MC4Rs on neurons in the medial preoptic area (mPOA) of the hypothalamus, increasing dopamine release — an excitatory neurotransmitter for sexual desire. Unlike PDE5 inhibitors, PT-141 works centrally through the CNS rather than peripherally on blood flow, addressing desire rather than just erectile mechanics.

Standard Dosing

Research indicates 1.75 mg administered via subcutaneous injection approximately 45 minutes before anticipated sexual activity.

Timing

45-60 minutes before anticipated sexual activity. Effects last 6-72 hours depending on individual response.

Cycle Duration

As-needed basis. Not intended for daily use.

Side Effects

• Nausea (most common, dose-dependent)
• Flushing
• Headache
• Nasal congestion (intranasal route)
• Transient blood pressure increase
• Skin darkening with repeated use

Contraindications

• Uncontrolled hypertension
• Cardiovascular disease
• Pregnancy and breastfeeding
• Use of other melanocortin agonists concurrently

Best Stacking Partners